Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VirbacVRBCF 80 Debt-to-EBITDA is 1.14 as of Dec. 2025, which is 8% above its 10-year median of 1.06. GuruFocus rates VRBCF with a GF Score™ of 80/100 and a GF Value™ of $351.99 (Fairly Valued). The stock has 2 warning signs investors should review. Among 691 Drug Manufacturers companies, Virbac ranks better than 61.94% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Virbac's Debt-to-EBITDA or its related term are showing as below:
VRBCF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.39 Med: 1.06 Max: 5.06
Current: 1.01
During the past 13 years, the highest Debt-to-EBITDA Ratio of Virbac was 5.06. The lowest was 0.39. And the median was 1.06.
VRBCF's Debt-to-EBITDA is ranked better than 61.94% of 691
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs VRBCF: 1.01
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Virbac Debt-to-EBITDA Related Terms
Virbac Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Virbac's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRBCF vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Virbac's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virbac Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Virbac's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Virbac's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Virbac (VRBCF) has a Debt-to-EBITDA of 1.14 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Virbac. This is near median its historical median of 1.06. Over the past decade, Virbac's Debt-to-EBITDA has ranged from 0.39 to 5.06. According to the industry distribution chart, Virbac ranks #263 out of 691 companies in the Drug Manufacturers industry, placing it in the top 38.1%.
Is Virbac's Debt-to-EBITDA too high?
Virbac's current Debt-to-EBITDA of 1.14 is near median its 10-year median of 1.06. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 5.06. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Virbac's value of 1.14 is 32.1% below this industry median. Based on the distribution chart, Virbac ranks #263 out of 691 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Virbac has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virbac's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Virbac ranks #263 out of 691 companies for Debt-to-EBITDA. This puts Virbac in the upper half of its industry. The industry median Debt-to-EBITDA is 1.68. Virbac's value of 1.14 is 32.1% below this benchmark. Historically, Virbac's own Debt-to-EBITDA has ranged from 0.39 to 5.06 over the past decade. While the company's 10-year median is 1.06 vs. the industry median of 1.68, Virbac has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virbac's current Debt-to-EBITDA of 1.14 is 32.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Virbac. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virbac's current Debt-to-EBITDA is 1.14, which is near median its own 10-year median of 1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (VRBCF) is currently considered Fairly Valued. The stock's GF Value™ is $351.99, compared to a current price of $383.25 — trading 8.9% above its estimated fair value. The current Debt-to-EBITDA is 1.14, which is near median its 10-year median of 1.06 and 32.1% below the Drug Manufacturers industry median of 1.68. Virbac's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Virbac (VRBCF), the current Debt-to-EBITDA is 1.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virbac (VRBCF) Overvalued in 2026?
Based on GuruFocus' analysis, Virbac stock appears to be overvalued.
The current stock price of $383.25 is trading 8.9% above its estimated GF Value™ of $351.99.
GuruFocus considers Virbac to be Fairly Valued.
Key valuation signals for VRBCF:
Debt-to-EBITDA: 1.14 (near median its 10-year median of 1.06)
GF Value™: $351.99 vs. price of $383.25 (8.9% above fair value)
Industry Position: 32.1% below the Drug Manufacturers median (#263 of 691)
No single metric tells the full story. See the VRBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
80GF Score
Get the complete analysis for VRBCF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRBCF has been successfully added to your 
